相关实验视频
Updated: May 7, 2026
08:02
Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
Published on: March 6, 2012
16.4K
术后放射治疗不能改善患有Masaoka-KogaIIB期胸腺瘤的患者的存活率:基于SEER数据库的倾向性得分匹配研究
Yonggang Shi1, Heng Chen, Shengbo Luo
1Department of Thoracic Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Medicine
|May 10, 2024
概括
手术后放射治疗 (PORT) 没有显著改善马萨奥卡-科加IIB阶段胸腺瘤的存活率. 这项以人口为基础的研究发现,在接受PORT和未接受PORT的患者之间,整体或癌症特异性存活率没有统计学上显著的差异.
科学领域:
- 在瘤学瘤学.
- 胸部外科手术 胸部外科手术
- 辐射瘤学 辐射瘤学
背景情况:
- 胸腺瘤是一种罕见的胸腺瘤.
- 马萨奥卡-科加IIB期胸膜瘤代表了侵袭性胸膜恶性瘤的特定子集.
- 术后放射治疗 (PORT) 在改善这些患者的治疗结果中的作用仍在争论中.
研究的目的:
- 为了研究PORT在Masaoka-KogaIIB期胸腺瘤的预后价值.
- 确定PORT是否为IIB阶段胸腺瘤患者提供显著的生存益处.
主要方法:
- 来自监测,流行病学和最终结果 (SEER) 数据库 (2004-2017) 的基于人口的队列的回顾性分析.
- 包括785名被诊断为Masaoka-KogaIIB期胸腺瘤的患者.
- 倾向性得分匹配用于平衡PORT和非PORT组之间的基线特征,然后进行多变量考克斯回归分析.
主要成果:
- 303名患者在PORT和非PORT组之间成功匹配,基线特征没有显著差异.
- 波特组的10年总生存率为65.2%,非波特组为59.6% (P=0.275).
- 针对癌症的10年生存率为PORT组的87.0%,非PORT组的84.4% (P=0.336).
结论:
- 术后放射治疗 (PORT) 没有显示出IIB阶段胸腺瘤的整体存活率在统计上有显著改善.
- 然而,PORT对IIB阶段胸腺瘤的癌症特异性存活率没有产生统计学上显著的改善.
- 根据这一SEER数据库分析,PORT似乎对患有Masaoka-KogaIIB阶段胸腺瘤的患者没有显著的生存益处.
相关概念视频
01:24Kaplan-Meier Approach
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...